NASDAQ
10.04.26 | 21:59
13,200 US-Dollar
-0,60 % -0,080
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.04. | Trevi Therapeutics, Inc.: Trevi Therapeutics to Participate in Upcoming Events | 1 | GlobeNewswire (USA) | ||
| 18.03. | These Analysts Revise Their Forecasts On Trevi Therapeutics Following Q4 Earnings | 2 | Benzinga.com | ||
| TREVI THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.03. | Trevi Therapeutics: Needham hebt Kursziel wegen geplanter Studien an | 1 | Investing.com Deutsch | ||
| 18.03. | Needham raises Trevi Therapeutics stock price target on trial plans | 1 | Investing.com | ||
| 18.03. | Cantor Fitzgerald reiterates Trevi Therapeutics stock Overweight rating | 2 | Investing.com | ||
| 18.03. | Trevi Therapeutics: Cantor Fitzgerald bekräftigt "Overweight"-Rating | 5 | Investing.com Deutsch | ||
| 18.03. | Trevi Therapeutics plans two pivotal phase III trials for IPF-related chronic cough as FDA alignment achieved | 4 | Seeking Alpha | ||
| 17.03. | Trevi Therapeutics GAAP EPS of -$0.06 beats by $0.04 | 1 | Seeking Alpha | ||
| 17.03. | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | 1.923 | GlobeNewswire (Europe) | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| 17.03. | Trevi Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 17.03. | Trevi Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.03. | Trevi Therapeutics, Inc.: Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026 | 2 | GlobeNewswire (USA) | ||
| 09.03. | Trevi Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.03. | Trevi Therapeutics: Oppenheimer bestätigt Kaufempfehlung nach Plänen für Phase-3-Studien | 1 | Investing.com Deutsch | ||
| 09.03. | Trevi Therapeutics stock gets Oppenheimer nod on Phase 3 plans | 2 | Investing.com | ||
| 09.03. | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough | 405 | GlobeNewswire (Europe) | The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter... ► Artikel lesen | |
| 08.01. | Trevi Therapeutics schedules FDA meeting for chronic cough program | 4 | Investing.com | ||
| 19.12.25 | Potenzial von Hustenmedikament: Stifel erhöht Kursziel für Trevi Therapeutics auf 18 Dollar | 3 | Investing.com Deutsch | ||
| 19.12.25 | Trevi Therapeutics stock price target raised to $18 by Stifel on cough drug potential | 4 | Investing.com | ||
| 05.12.25 | Trevi Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,40 | -0,06 % | BioNTech, Newron und Emyria: Biotech-Unternehmen rücken in den Fokus einer neuen Substanzdebatte | ||
| EVOTEC | 4,530 | +0,09 % | Evotec-Aktie profitiert von Milliarden-Deal: Gilead kauft Tubulis | Der US-Pharmakonzern Gilead setzt seine Einkaufstour im Biotech-Sektor fort und übernimmt das deutsche Krebsforschungsunternehmen Tubulis für bis zu fünf Milliarden Dollar. Die Transaktion zeigt, wie... ► Artikel lesen | |
| MEDIGENE | 0,025 | -18,83 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| VALNEVA | 2,668 | -1,11 % | EXKLUSIV zu Valneva: Analysten sehen massives Kurspotenzial - Die Chance die sich zum Wochenstart ergibt | ||
| AMGEN | 299,00 | -0,10 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| NOVAVAX | 6,860 | -1,01 % | Activist investor revives campaign to overhaul Novavax board | ||
| STRYKER | 289,50 | +0,10 % | Stryker confident of 2026 outlook despite Q1 impact from cyberattack | ||
| BIOGEN | 147,04 | -0,28 % | Biogen to acquire Apellis in $5.6bn deal | ||
| ILLUMINA | 102,88 | -0,23 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 43,695 | 0,00 % | CRISPR Therapeutics-Aktie: Milliarden mit Gentherapie CASGEVY? | CRISPR Therapeutics vollzieht den Übergang von einem reinen Forschungsunternehmen zu einem kommerziellen Biotechnologieanbieter. Mit ersten nennenswerten Umsätzen und einer breiten Pipeline an innovativen... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 631,90 | -1,06 % | Piper Sandler reiterates Overweight rating on Regeneron stock at $875 | ||
| BRAIN BIOTECH | 2,470 | +1,23 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Patent
BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie
23.03.2026 / 11:05 CET/CEST
Für... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,227 | +2,90 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results | Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,950 | -0,86 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen |
Das Unternehmen TREVI THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,080 (-0,60 %) liegt der Kurs bei 13,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TREVI THERAPEUTICS INC finden Sie auf Wallstreet Online.